Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
Stock Information for Hepion Pharmaceuticals Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals to Highlight AI-POWR(TM) at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress